Re: Potential use of imatinib in Ewing's sarcoma: evidence for in vitro and in vivo activity.
Tamborini
Elena
E
Bonadiman
Lorena
L
Albertini
Veronica
V
Pierotti
Marco A
MA
Pilotti
Silvana
S
D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001549:Benzamides; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D004791:Enzyme Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D000068877:Imatinib Mesylate; D066298:In Vitro Techniques; D015513:Oncogene Proteins / Q000378:metabolism*; D010766:Phosphorylation; D010879:Piperazines / Q000494:pharmacology* / Q000627:therapeutic use; D011233:Precipitin Tests; D019009:Proto-Oncogene Proteins c-kit; D011743:Pyrimidines / Q000494:pharmacology* / Q000627:therapeutic use; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012512:Sarcoma, Ewing / Q000188:drug therapy* / Q000378:metabolism
D000970:Antineoplastic Agents; D001549:Benzamides; D004791:Enzyme Inhibitors; D015513:Oncogene Proteins; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D019009:Proto-Oncogene Proteins c-kit